A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Trial Identifier:	D5330C00017
Sponsor:	AstraZeneca
NCTID::	NCT05514132
Start Date:	September 2022
Primary Completion Date:	October 2023
Study Completion Date:	April 2025
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Beijing, CN, 100021
CN	Shandong, CN

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.